source
- Merck reports positive mid-stage results for Prometheus' tulisokibart in painful skin diseaseMerck presented new data from a mid-stage trial of tulisokibart, a drug acquired through its $10.8 billion purchase of Prometheus Biosciences. The trial evaluated multiple dose levels in patients…
- Mid-dose petrelintide shows strongest weight loss in phase-2 trial, paving way for pivotal studyRoche and Zealand Pharma released new phase-2 data for petrelintide, an amylin analog being developed for obesity treatment. In the Zupreme 1 trial, the 5 mg dose achieved the greatest mean weight…